Alan M. Miller, MD, PhD, has a long and distinguished career in oncology and clinical research. For the past three and a half years he has helped build an oncology and clinical research network for SCL Health, with nine cancer centers in Colorado and Montana. Prior to joining SCL Health, Dr. Miller served as the system chief of oncology for Baylor Scott and White Health, as well as director of the Charles A. Sammons Cancer Center at Baylor University Medical Center. Dr. Miller has also led the blood and marrow transplant programs at the University of Florida and Tulane University, the latter which he founded. At Tulane he served in medical school and health sciences leadership positions, and was part of the team that brought that institution back from the devastation of Hurricane Katrina.
Dr. Miller has been a principal investigator and co-investigator on numerous cancer clinical trials, and early in his career held a prestigious American Cancer Society Career Development Award. Other notable activities include serving as vice chairman of the Louisiana Health Care Commission and chairman of the Louisiana Cancer Research Consortium. Dr. Miller has published extensively in peer-reviewed journals including, Nature, Blood, and the Journal of Clinical Oncology.
Madeleine Kane, MD, PhD, is a professor of medicine, medical oncology at the University of Colorado School of Medicine. Her interests include head and neck cancer, GI malignancies, thyroid cancer, neuroendocrine cancers, and AIDS malignancies.
Scott A. Kono, DO, MS, was honored to serve as chief resident at the University of Kansas School of Medicine and chief fellow during his oncology training at the University of Colorado. After fellowship, Dr. Kono served as an assistant professor at Emory University, primarily treating cancers of the head/neck and lung.
Dr. Kono's areas of focus include gastrointestinal, neuroendocrine, sarcoma, breast, lung, hematologic, head and neck malignancies, and benign hematology. In 2019, he was recognized as Top Doctor by 5280 Magazine.
Dr. Bupathi is a board-certified medical oncologist, and he joined Rocky Mountain Cancer Centers in 2017. He specializes in solid tumors with an advanced subspecialty expertise in breast cancers and genitourinary cancers (adrenal, bladder, kidney, penile, prostate, and testicular). Dr. Bupathi is deeply committed to personalized care, always taking the time to listen and understand what matters to his patients. He is valued by his patients, peers, and colleagues for his excellent clinical judgment. He makes it a point to be well-prepared for patient visits by reviewing charts and consulting with colleagues and team members prior to appointments. His patients have his full attention and he is devoted to their best interests.
Dr. Bupathi participates in many tumor boards, where he collaborates with other cancer specialists including surgeons, radiologists, pathologists, and radiation oncologists. This allows him to provide a comprehensive, multi-disciplinary approach to cancer treatment recommendations such as chemotherapy, targeted therapies, and immunotherapies. Dr. Bupathi has a strong interest in the field of personalized medicine and how genomics and molecular pathways impact cancer treatment options. He serves as principal investigator for many Phase I, Phase II, and Phase III studies, and he emphasizes the importance of participating in clinical research trials whenever possible to ensure patients are receiving the most timely, cutting-edge treatment for their disease. In addition to Rocky Mountain Cancer Centers, Dr. Bupathi also sees patients for Phase I clinical research trials at Sarah Canon Research Institute in Denver.
Allen L. Cohn, MD, is a medical oncologist affiliated with multiple hospitals in the Denver area, including Avista and Castle Rock Adventist Hospitals. Dr. Cohn received his medical degree from the University of Maryland School of Medicine and has been in practice for more than 20 years.
Laura R. Dickinson, PA, began her studies at the University of Denver where she completed a master’s degree in molecular biology, later moving to Pittsburgh to complete her physician assistant studies. Laura worked in oncology at the University of Pittsburgh for four years in a specialty clinic for patients with melanoma and sarcoma, after which she moved to Scotland where she worked in orthopedic surgery for a few years.
Wells A. Messersmith, MD, joined the University of Colorado School of Medicine faculty in August 2007 as the director of gastrointestinal medical oncology. He is also the head of the division and co-leader of the development team in the division of medical oncology.
Dr. Messersmith is an active participate in the drug development program and has his own clinical and translational laboratory, funded by the National Cancer Institute, that investigates developmental therapeutics for targeted therapies as well as correlative studies for use on human tissue samples.
Outside of the university, Dr. Messersmith is a member of multiple national committees, including NCI GI Steering Committee, NCI Colon Cancer Task Force, National Comprehensive Cancer Network (NCCN) Committee on Colon/Rectal/Anal Cancers, NCCN Investigator Steering Committee, and the Medical Oncology Committee of the American Board of Internal Medicine.